Nuvalent
Latest round
- Series B
Last raised
- May 2021
Total raised
- $185M
Investors
- 12
About Nuvalent
, is a biotechnology company that develops therapies for clinically proven kinase targets in cancer and designs innovative molecular structures that enable therapies to treat tumors. The company was founded by James R. Porter and Matthew Shair.75 million shares at USD 17 per share on the Nasdaq. The company currently has 31 employees. Nuvalent, Inc. provides medicines with the potential to achieve deep and durable responses with minimal side effects for patients with cancer. The company has 2 programs; NUV-520 which is a novel ROS1-selective inhibitor and potential therapy for patients with advanced NSCLC (Non-small cell lung cancer) driven by a ROS1 fusion. And NUV-655, a novel ALK-selective inhibitor created for patients with advanced NSCLC tumors driven by an ALK fusion. Nuvalent plans to begin clinical trials in patients with ROS1-positive non-small cell lung cancer and other advanced solid tumors in the second half of 2021. The firm is also exploring a pipeline of programs with a focus on addressing the limitations of existing therapies for other clinically proven kinase targets in oncology.
Who invested in Nuvalent
12 investors across 2 rounds
See all investors in Nuvalent
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Nuvalent
Who invested in Nuvalent?
Nuvalent has 12 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Nuvalent raised?
Nuvalent has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Nuvalent last raise money?
Nuvalent's most recent round on record is a Series B, in May 2021.
What does Nuvalent do?
, is a biotechnology company that develops therapies for clinically proven kinase targets in cancer and designs innovative molecular structures that enable therapies to treat tumors.
Where is Nuvalent headquartered?
Nuvalent is headquartered in Cambridge, US.
Which VCs invest in companies like Nuvalent?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Nuvalent's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Nuvalent? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.